Anti-VAV1 (phospho Y174) 抗体 [EP510Y] (ab76225)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP510Y] to VAV1 (phospho Y174)
- Suitable for: Flow Cyt (Intra), WB, ICC/IF, Dot blot
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-VAV1 (phospho Y174) antibody [EP510Y]
VAV1 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EP510Y] to VAV1 (phospho Y174) -
由来種
Rabbit -
アプリケーション
適用あり: Flow Cyt (Intra), WB, ICC/IF, Dot blotmore details
適用なし: IHC-P or IP -
種交差性
交差種: Human -
免疫原
Synthetic peptide within Human VAV1 (phospho Y174). The exact sequence is proprietary.
-
ポジティブ・コントロール
- WB: Jurkat cell lysate treated with pervanadate. ICC/IF: Jurkat cell lysate treated with pervanadate. Flow Cyt (intra): WB: Jurkat cell lysate treated with pervanadate.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EP510Y -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
- Alexa Fluor® 488 Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab237470)
- Alexa Fluor® 647 Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab237471)
- FITC Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab237472)
- Anti-VAV1 (phospho Y174) antibody [EP510Y] - BSA and Azide free (ab238424)
- APC Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab319292)
- PE Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab319439)
- Alexa Fluor® 594 Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab319785)
- Alexa Fluor® 555 Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab319926)
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab76225の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Flow Cyt (Intra) |
Use at an assay dependent concentration.
|
|
WB | (1) |
1/1000. Detects a band of approximately 101 kDa (predicted molecular weight: 101 kDa).
|
ICC/IF |
1/100 - 1/500.
|
|
Dot blot |
Use at an assay dependent concentration.
|
特記事項 |
---|
Flow Cyt (Intra)
Use at an assay dependent concentration. |
WB
1/1000. Detects a band of approximately 101 kDa (predicted molecular weight: 101 kDa). |
ICC/IF
1/100 - 1/500. |
Dot blot
Use at an assay dependent concentration. |
ターゲット情報
-
機能
Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation. -
組織特異性
Widely expressed in hematopoietic cells but not in other cell types. -
配列類似性
Contains 1 CH (calponin-homology) domain.
Contains 1 DH (DBL-homology) domain.
Contains 1 PH domain.
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 SH2 domain.
Contains 2 SH3 domains. -
ドメイン
The DH domain is involved in interaction with CCPG1. -
翻訳後修飾
Phosphorylated on tyrosine residues. - Information by UniProt
-
参照データベース
- Entrez Gene: 7409 Human
- Omim: 164875 Human
- SwissProt: P15498 Human
- Unigene: 116237 Human
-
別名
- Oncogene vav antibody
- p95Vav antibody
- Proto-oncogene vav antibody
see all
画像
-
All lanes : Anti-VAV1 (phospho Y174) antibody [EP510Y] (ab76225) at 1/1000 dilution
Lane 1 : Jurkat (human T cell leukemia T lymphocyte) whole cell lysate
Lane 2 : Jurkat treated with 50mM pervanadate for 5minutes whole cell lysate
Lane 3 : Jurkat treated with 50mM pervanadate for 5min whole cell lysate 10 µg. Then the membrane was incubated with alkaline phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 101 kDaBlocking and diluting buffer: 5% NFDM/TBST
-
Immunocytochemistry/Immunofluorescence analysis of Untreated Jurkat cells and Pervanadate (1mM,30min) treated Jurkat cells labelling VAV1 (phospho Y174) with purified ab76225 at 1/500. Cells were fixed with 4% PFA and permeabilized with 0.1% Triton X-100, and counterstained with ab7291 anti-Tubulin (mouse mAb) 1:1000 (1ug/ml). An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody (Ab150077). Nuclei counterstained with DAPI (blue).
Negative Control 1: Rabbit primary antibody and anti-mouse secondary antibody(ab150120)
Negative Control 2: Mouse primary antibody(ab7291) and anti-rabbit secondary antibody(ab150077)
-
Intracellular Flow Cytometry analysis of Jurkat (human acute T cell leukemia) untreated/treated with 1mM pervanadate for 30min cells labeling VAV1 with unpurified ab76225 at 1/200 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluorr® 488) (1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control. Untreated control (Green).
-
Dot blot analysis of VAV1 (pY174) peptide (Lane 1) and VAV1 non-phospho peptide (Lane 2) labelling VAV1 (phospho Y174) with ab76225 at a dilution of 1/1000. A Peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/2500.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (18)
ab76225 は 18 報の論文で使用されています。
- Ni J et al. Esculin alleviates LPS-induced acute lung injury via inhibiting neutrophil recruitment and migration. Int Immunopharmacol 119:110177 (2023). PubMed: 37068336
- Cortes JR et al. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma. Cell Rep 39:110695 (2022). PubMed: 35443168
- Raiter A et al. A novel role for an old target: CD45 for breast cancer immunotherapy. Oncoimmunology 10:1929725 (2021). PubMed: 34104545
- Alon D et al. Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Front Med (Lausanne) 8:675963 (2021). PubMed: 34414199
- Guedan S et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest 130:3087-3097 (2020). PubMed: 32069268